Therapies: PharmaEssentia Ensures Reliable Interferon Access

Therapies: PharmaEssentia Ensures Reliable Interferon Access PharmaEssentia (TWSE: 6446), a leading global biopharmaceutical company, has reaffirmed its commitment to ensuring robust and reliable access to critical interferon therapies, particularly in light of the reported global shortage of Pegasys® (peginterferon alfa-2a).…

Read MoreTherapies: PharmaEssentia Ensures Reliable Interferon Access

Voom CEO Dr. Neal Blitz Guest Edits January 2025 Clinics in Podiatric Medicine Issue on MIS

Voom CEO Dr. Neal Blitz Guest Edits January 2025 Clinics in Podiatric Medicine Issue on MIS Voom™ Medical Devices, Inc. (“Voom”), a pioneering company revolutionizing minimally invasive foot and ankle surgery, is excited to announce that its Founder and CEO,…

Read MoreVoom CEO Dr. Neal Blitz Guest Edits January 2025 Clinics in Podiatric Medicine Issue on MIS

Invests $150M in Patho Care via PathoCare Holdings, Hamershlag Private Capital

Invests $150M in Patho Care via PathoCare Holdings, Hamershlag Private Capital Hamershlag Private Capital Management Limited (HPCM), a prominent health technology investment firm, invests in Patho Care, LLC, a leading innovator in non-invasive point-of-care diagnostic testing. Patho Care’s groundbreaking Raman…

Read MoreInvests $150M in Patho Care via PathoCare Holdings, Hamershlag Private Capital